Image

Global Musculoskeletal Disorders Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Musculoskeletal Disorders Drugs Market, By Type (Rheumatoid Arthritis, Osteoporosis, Osteoarthritis, Psoriatic Arthritis, Fibromyalgia, Ankylosing Spondylitis, Others), Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2029.

Musculoskeletal Disorders Drugs Market

Musculoskeletal Disorders Drugs Market Analysis and Size

The global musculoskeletal disorders drugs market is expected to witness significant growth during the forecast period. The growth of musculoskeletal disorders drugs market boosted by the growing cases of musculoskeletal disorders and promising pipeline drugs. Regulatory changes likely lead to increased costs associated with new product development and service offerings to clients. COVID-19 also had left a major impact on the population and the market growth.

Data Bridge Market Research analyses a growth rate in the global musculoskeletal disorders drugs market in the forecast period 2022-2029. The expected CAGR of global musculoskeletal disorders drugs market is tend to be around 5.50% in the mentioned forecast period. The market was valued at USD 97.73 billion in 2021, and it would grow upto USD 150 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Musculoskeletal disorders are a type of connective tissue disease affecting the muscles, bones, and joints usually seen in elderly population. It occurs when protective tissue cartilage presents at the end of the bone and are progressively degenerated and causes severe pain and discomforts which eventually affects everyday activities.

Musculoskeletal Disorders Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Rheumatoid Arthritis, Osteoporosis, Osteoarthritis, Psoriatic Arthritis, Fibromyalgia, Ankylosing Spondylitis, Others), Treatment Type (Medication, Surgery, Therapy), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S.)

Market Opportunities

  • Increase in Elderly Population

Global Musculoskeletal Disorders Drugs Market Dynamics

Drivers

  • High Prevalence of Arthritis

Its been witnessed that more than 350 million people have arthritis all over the globe. In the U.S., 1 in 4 adults have been reported with arthritis in 2020. It’s estimated to be 78 million by the year 2040. This boosts the market growth.

  • Increased alcohol intake

Increased alcohol consumption is expected to drive the expansion of the musculoskeletal disorders market during the forecast period as a result of the association between increased incidence of joint disorders and  alcohol consumption.

Opportunities

  • Increase in Elderly Population

Life expectancy is growing around the world, which has led to an increase in the aging population. This trend positively impacts the industry by increasing the incidence of the disease and creating per capita demand for its remedies.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel who are unable to perform the treatments could curb the growth of the global musculoskeletal disorders drugs market over a forecast period.

  • High Cost

The huge expenditure required for treatment process surely hamper the market growth.

This global musculoskeletal disorders drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global musculoskeletal disorders drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Musculoskeletal Disorders Drugs Market

With the onset of COVID-19, several countries abandoned all non-emergency surgical procedures so that healthcare professionals only focus on patients with COVID-19. Thus, the market faced a huge loss during the pandemic. Although, during the thisrd wave and post-pandemic era, the market witnessed an outgrow and started working rapidly through a significant backlog of postponed surgeries.

Global Musculoskeletal Disorders Drugs Market Scope

The global musculoskeletal disorders drugs market is segmented on the basis of type, treatment type, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Spondylarthritis
  • Juvenile Idiopathic Arthritis
  • Psoriatic Arthritis
  • Fibromyalgia
  • Others

Treatment Type

  • Medication
  • Therapy
  • Surgery
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Musculoskeletal Disorders Drugs Market Regional Analysis/Insights

The global musculoskeletal disorders drugs market is analysed and market size insights and trends are provided by type, treatment type, route of administration, end-user and distribution channel as referenced above.

The major countries covered in the global musculoskeletal disorders drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the market due to the global leaders in research and development activities and vulnerable musculoskeletal disorders population.

Asia-Pacific is expected to account for the largest market share because of the developing healthcare facilities, huge number of generic manufacturers and increase in government initiatives and specialist communities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Musculoskeletal Disorders Drugs Market Share Analysis

The global musculoskeletal disorders drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global musculoskeletal disorders drugs market.

Key players operating in the global musculoskeletal disorders drugs market include:

  • Pfizer Inc. (U.S.)
  • Abbvie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Amgen Inc. (U.S.)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Merck & Co Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceuticals Industries Ltd. (Israel)
  • AstraZeneca (U.K.)
  • Ampio Pharmaceuticals Inc. (U.S.)
  • Lilly (U.S)


SKU-
Why Choose Us


Frequently Asked Questions

The musculoskeletal disorders drugs market was USD 97.73 billion in 2021.
The musculoskeletal disorders drugs market is projected to grow at a CAGR of 5.50% during the forecast period of 2022-2029.
North America dominates the market due to the global leaders in research and development activities and the vulnerable musculoskeletal disorders population.
The top player are Pfizer Inc. (U.S.), Abbvie Inc. (U.S.), Novartis AG (Switzerland), Amgen Inc. (U.S.), Boehringer Ingelheim International GmbH. (Germany), Merck & Co Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceuticals Industries Ltd. (Israel), AstraZeneca (U.K.), Ampio Pharmaceuticals Inc. (U.S.), Lilly (U.S.).